Concomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patients

AIDS Research and Human Retroviruses

Volumn 24, Issue 7, 2008, Pages 897-901

  Sathia, Leena ^a   Obiorah, Ifeyinwa ^a   Taylor, Graham ^a   Kon, Onn ^a   O'Donoghue, Marie ^a   Gibbins, Sara ^b   Walsh, John ^a   Winston, Alan ^a  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; NEVIRAPINE; RIFAMPICIN;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG MONITORING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HEPATITIS, TOXIC; HIV INFECTIONS; HIV-1; HUMANS; MALE; NEVIRAPINE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 48749132940     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0277     Document Type: Article

References (16)

1. Heylen R and Miller R: Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients: Part 2. Genitourin Med 1997;73:5-11.
2. Pozniak A, Miller R, Lipman M, et al.: BHIVA treatment guidelines for tuberculosis (TB)/HIV infection 2005. HIV Med 2005;6(S2):62-83.
3. Mallon P, Ray J, and Cooper D: Effect of therapeutic drug monitoring on outcome in antiretroviral experienced HIV-infected patients. J Clin Virol 2003;26(2):223-227.
4. Marzolini C, Telenti A, Decosterd LA, et al.: Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS 2001;15:71-75.
5. Available at www.hivpharmacology.com.
6. Van Heeswijk R, Veldkamp A, Mulder J, et al.: The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 2000;14(8):F77-82.
7. Ribera E, Pou L Lopez R, et al.: Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr 2001;28:450-453.
8. Dean G, Back D, and de Ruiter A: Effect of tuberculosis therapy on nevirapine trough plasma concentrations. AIDS 1999;13:2489-2491.
9. Oliva J, Moreno S, Sanz J, et al.: Coadministration of rifampin and nevirapine in HIV-infected patients with tuberculosis. AIDS 2003;17:637-638.
10. Autar R, Mahanontharit A, Anekthananon T, et al.: What is the clinical relevance of the drug interaction between nevirapine and rifampin. XV International AIDS Conference, 2004, Abstract B11784.
11. Ramachandran G, Hemanthkumar A, Rajasekaran S, et al.: Increasing nevirapine dose can overcome reduced bioavail-ability due to rifampicin coadministration. J Acquir Immune Defic Syndr 2006;42(1):36-41.
12. Haas R, Ribaudo H, Kim R, et al.: A common CYP2B6 variant is associated with pharmacokinetic and central nervous system side effects: AACTG Study NWCS214. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 8-11, 2004, Abstract 133.
13. Brennan-Benson P, Lyus R, Harrison T, et al.: Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: One size does not fit all. AIDS 2005;19(14):1541-1543.
14. Li A, Reith M, Rasmussen A, et al.: Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: Evaluation of rifampin, rifapentine, rifabutin. Chem Biol Interact 1997;107:17-30.
15. Pozniak A, Miller R, and Ormerod L: The treatment of tuberculosis in HIV-infected persons. AIDS 1999;13(4):435-445.
16. Breen R, Miller R, Gorsuch T, et al.: Adverse events and treatment interruption in tuberculosis patients with and without HIV infection. Thorax 2006;61(9):791-794.